Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia-Reference-Cited by-同舟云学术

Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia

Published:2018-02-12 Issue:3 Volume:137 Page:187-205
ISSN:0001-690X
Container-title:Acta Psychiatrica Scandinavica
language:en
Short-container-title:Acta Psychiatr Scand

Author:

Galling B.¹²³,Vernon J. A.²,Pagsberg A. K.⁴⁵,Wadhwa A.²,Grudnikoff E.⁶,Seidman A. J.⁷,Tsoy-Podosenin M.⁸,Poyurovsky M.⁹¹⁰,Kane J. M.²³¹¹,Correll C. U.¹²³¹¹^ORCID

Affiliation:

1. Department of Child and Adolescent Psychiatry; Charité Universitätsmedizin; Berlin Germany

2. The Zucker Hillside Hospital, Psychiatry Research; Northwell Health; Glen Oaks NY USA

3. Hofstra Northwell School of Medicine; Hofstra University; Hempstead NY USA

4. Child and Adolescent Mental Health Center; Mental Health Services; Capital Region of Denmark; Glostrup Denmark

5. Faculty of Health and Medical Sciences; Department of Clinical Medicine; University of Copenhagen; Copenhagen Denmark

6. South Oaks Hospital; Amityville NY USA

7. Department of Psychology; Iowa State University; Ames IA USA

8. Department of Psychiatry; St John's Episcopal Hospital; New York NY USA

9. Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Haifa Israel

10. Tirat Carmel Mental Health Center; tirat Carmel Israel

11. The Feinstein Institute for Medical Research; Manhasset NY USA

Funder

National Institute of Mental Health

Publisher

Wiley

Subject

Psychiatry and Mental health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/acps.12854/fullpdf

Reference98 articles.

1. Past and present progress in the pharmacologic treatment of schizophrenia;Kane;J Clin Psychiatry,2010

2. Schizophrenia;Kahn;Nat Rev Dis Primers,2015

3. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery;Carlsson;Dialogues Clin Neurosci,2006

4. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia;Carbon;CNS Spectr,2014

5. Emerging drugs for schizophrenia: an update;Köster;Expert Opin Emerg Drugs,2014

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia;Pharmaceuticals;2024-01-28

2. Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations;Schizophrenia Research;2023-10

3. Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs;BMJ Mental Health;2023-10

4. An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders;Molecular Psychiatry;2023-09

5. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects;Schizophrenia;2023-05-26